Results 21 to 30 of about 36,269 (231)
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Pathologica, 2023 Summary Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal prognosis. Several studies have investigated the genomic profile of CCA and identified numerous druggable genetic alterations, including FGFR2 fusions ...
Valentina Angerilli +6 more
semanticscholar +1 more source
FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
Journal of Translational Medicine, 2021 Background Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no ...
Yue Wang +8 more
doaj +1 more source
ACS Medicinal Chemistry Letters, 2023 Fibroblast growth factor receptors (FGFRs) are transmembrane receptor tyrosine kinases that regulate multiple physiological processes. Aberrant activation of FGFR2 and FGFR3 has been linked to the pathogenesis of many tumor types, including ...
Minh-Hai Nguyen +25 more
semanticscholar +1 more source
Cancer Discovery, 2022 FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined ...
Qibiao Wu +22 more
semanticscholar +1 more source
British Journal of Cancer, 2022 Background Cholangiocarcinoma (CCA) is a primary malignancy of the biliary tract with a dismal prognosis. Recently, several actionable genetic aberrations were identified with significant enrichment in intrahepatic CCA, including FGFR2 gene fusions with ...
O. Neumann +21 more
semanticscholar +1 more source
FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. [PDF]
PLoS ONE, 2014 Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene ...
Anjili Mathur +5 more
doaj +1 more source
Journal of Clinical and Translational Hepatology, 2023 Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its ...
Yining Zou +8 more
semanticscholar +1 more source
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)
International Journal of Molecular Medicine, 2009 FGFR2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms functioning as FGF receptors with distinct expression domain and ligand specificity. FGFR2 plays oncogenic and anti-oncogenic roles in a context-dependent manner. Single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 gene are associated with breast cancer through allelic ...
Yuriko, Katoh, Masaru, Katoh
openaire +3 more sources
Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer
Biomedicines, 2023 Background: c-mesenchymal epithelial transition factor receptor (c-MET) and fibroblast growth factor receptor 2 (FGFR2) amplification have been identified as factors associated with advanced stage and poor prognosis in gastric cancer (GC). While they are
Seonggyu Byeon +4 more
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2023 Heart failure is a leading cause of death and is often accompanied by activation of quiescent cardiac myofibroblasts, which results in cardiac fibrosis. In this study, we aimed to identify novel circular RNAs that regulate cardiac fibrosis.
Anna Jeong +21 more
semanticscholar +1 more source